FindTrial
Sign In

Safety analysis of rivaroxaban in clinical use

Safety analysis of rivaroxaban in clinical use

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600117135
Enrollment
Unknown
Registered
2026-01-20
Start date
2025-03-17
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver cirrhosis

Interventions

Compensatory stage of liver cirrhosis:None
decompensated liver cirrhosis:None
Non-cirrhosis group:None

Sponsors

Shanghai Public Health Clinical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Select the data of all patients who received rivaroxaban treatment at Shanghai Public Health Clinical Center from January 2018 to the present.

Exclusion criteria

Exclusion criteria: Does not involve inclusion and exclusion criteria

Design outcomes

Primary

MeasureTime frame
Prothrombin Time;—

Countries

China

Contacts

Public ContactYan Yufeng

Shanghai Public Health Clinical Center

yanyufeng@dingtalk.com+86 189 3081 3985

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026